STOCKHOLM, SWEDEN--(Marketwire - May 31, 2012) - Birgitte Volck has been appointed Senior Vice President, Chief Medical Officer at Sobi with responsibility for Clinical Development, Regulatory Affairs, Drug Safety and Medical Affairs.
Birgitte Volck is currently Executive Development Director, Bone, Neuroscience & Inflammation at Amgen Limited in Uxbridge, UK. She has held several senior positions within Amgen since 2007, including Executive Medical Director, Nordic & Baltic Region. Prior to Amgen she was Nordic Medical Director & Project Director at Genzyme A/S in Denmark 2004-2007, and Vice President, Clinical Development & Medical Affairs at Pharmexa A/S in Denmark 2001-2004.
During 1991-2000 she had various clinical and scientific assignments, mainly within rheumatology, at the Copenhagen University Hospitals. She holds a PhD and has published a number of scientific papers related to inflammation, connective tissue metabolism, biomarkers and arthritis.
Birgitte Volck, 49 years, is MD and PhD from the University of Copenhagen. She will report to CEO Geoffrey McDonough and will be a member of the Executive Leadership Team. She will assume her position on August 1, 2012.
“We are delighted to welcome Birgitte to Sobi. With her extensive experience in drug development and integrated and patient focused Medical Affairs, Birgitte will bring a perspective and drive to our medical organization as we advance our life cycle management and late stage pipeline projects,” says Geoffrey McDonough, CEO of Sobi.
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 31 May 2012 at 08.30 CET.
Sobi press release May 31, 2012 in pdf format: http://hugin.info/134557/R/1616170/515367.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE [HUG#1616170]
For further information, please contact:
Asa Stenqvist
Head of Communications and Investor Relations
Tel.: +46 8 697 21 88
